The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
Arginine starvation depletes the micronutrients required for DNA synthesis and interferes with both thymidylate synthetase activity and DNA repair pathways in preclinical models of hepatocellular carcinoma (HCC). Pegylated arginine deiminase (ADI‐PEG 20), an arginine degrader, potentiates the cytotoxic activity of platinum and pyrimidine antimetabolites in HCC cellular and murine models...
Background
The objective of this study was to assess whether entecavir (ETV) in combination with interferon‐α (IFN‐α) could reduce hepatocellular cancer (HCC) and extrahepatic cancers (EHCs) in patients with chronic hepatitis B (CHB).
Methods
The cohort consisted of 4194 patients with CHB treated with ETV combined with IFN‐α or ETV monotherapy at a tertiary hospital in Beijing, China, from January...
Background
This article investigated whether robotic‐assisted liver surgery versus laparoscopic liver surgical treatment of hepatocellular carcinoma (HCC) has similar or different short‐ and long‐term clinical outcomes.
Methods
A total of 3049 patients from the National Cancer Database who received minimally invasive surgery (ie, robotic or laparoscopic surgery) for stage I HCC cancers between...
The use of radiation for primary liver cancers has historically been limited because of the risk of radiation‐induced liver disease. Treatment fields have become more conformal because of several technical advances, and this has allowed for dose escalation. Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy, is now able to safely treat liver tumors to ablative...
Background
The cost effectiveness of atezolizumab plus bevacizumab (atezo‐beva) versus nivolumab treatment for advanced or unresectable hepatocellular carcinoma is still uncertain. In this study, the cost effectiveness of these treatments was assessed in the United States.
Methods
A cost‐effectiveness analysis integrating a network meta‐analysis framework was performed using data from the IMbrave150...
Background
The correlation between thalassemia and malignancies other than hepatocellular carcinoma (HCC) and the possible relationship between other hemoglobinopathies and tumor risk have been poorly evaluated.
Methods
Eight Italian specialized centers evaluated the incidence of malignant neoplasms in hemoglobinopathies as well as their sites and features. The study cohort included 4631 patients...
Background
The optimal intervals for follow‐up after hepatocellular carcinoma (HCC) patients undergo curative liver resection (LR) remain unclear. This study aimed to establish a risk‐based post‐resection follow‐up strategy.
Methods
Patients that were diagnosed with HCC and received LR from three hospitals in China were included. The risk‐based strategy was established based on the random survival...
Background
Although the efficacy of atezolizumab has been demonstrated in randomized controlled trials, its long‐term efficacy and association with adverse events in real‐world practice are unknown. This study was designed to shed light on these issues.
Methods
In this multicenter retrospective study, data were collected from patients with advanced hepatocellular carcinoma treated with atezolizumab...
This commentary reviews top advances in hepatobiliary cancer research in 2021–2022, focusing on leveraging immunotherapeutics in combination with other therapies earlier in the disease course and targeted to patient's individualized biomarkers that may predict response or resistance to checkpoint inhibitors.
Background
Clinical trials suggest α‐fetoprotein (AFP) reduction may be prognostic among patients with advanced hepatocellular carcinoma. However, the association of AFP reduction with outcomes in real‐world settings is unclear.
Methods
Patients with advanced hepatocellular carcinoma between January 1, 2011, and June 30, 2021, first‐line tyrosine kinase inhibitor, and baseline and posttreatment...
Background
Nonalcoholic fatty liver disease (NAFLD) is a major contributor to the rising incidence of hepatocellular carcinoma (HCC). Magnesium is a major cation in cellular activities. Epidemiological data on magnesium level and its relation to HCC are sparse. This study aimed to examine the associations between serum levels of magnesium and the risk of HCC among patients with NAFLD.
Methods
A...
Background
Despite resection surgery as a curative therapy for hepatocellular carcinoma (HCC), the high rate of postoperative HCC recurrence remains a big challenge for patient survival. Chronic hepatitis B virus (HBV) infection is the most important risk factor for HCC. Deletion mutation in the HBV pre‐S2 gene leads to expression of an essential viral oncoprotein called pre‐S2 mutant and represents...
Background
US‐born Latinos have a higher incidence of hepatocellular carcinoma (HCC) than foreign‐born Latinos. Acculturation to unhealthy lifestyle behaviors and an immigrant self‐selection effect may play a role. In this study, the authors examined the influence of generational status on HCC risk among Mexican American adults.
Methods
The analytic cohort included 31,377 self‐reported Mexican...
Background
Lenvatinib is approved as a first‐line treatment for patients with unresectable and/or recurrent hepatocellular carcinoma (HCC). Lenvatinib achieved promising clinical benefits in REFLECT but was associated with clinically significant treatment‐emergent hypertension (CSTE‐HTN, a grouped term), a common class effect of tyrosine kinase inhibitors. This post hoc analysis assessed the impact...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.